Navigation Links
Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
Date:1/15/2008

PHILADELPHIA, Jan. 15 /PRNewswire/ -- Premier Research Group plc (AIM: PRG), the international pharmaceutical services group, announces the appointment of Patrick Melvin as Senior Director, Clinical Trial Management specializing in oncology-related research. In this position, Mr. Melvin will play a leading role in the operations, strategic planning and corporate development of Premier Research's growing portfolio of oncology business.

Over the past nine years, Mr. Melvin managed hematology/oncology programs ranging from Phase I first-in-man studies through pivotal global Phase III programs. His early phase experience included multiple variations of early phase designs, including PK/PD studies, traditional dose-escalating maximum tolerated dose studies, Simon two-stage studies, and adaptive design studies. The later phase studies included extensive global experience in hematology/oncology clinical research including clinical program and client activities in the United States, Western and Eastern Europe, Latin America, and Asia. His responsibilities incorporated consulting with clients on clinical development plans and protocol design for new hematology/oncology studies. Mr. Melvin began his clinical research career as a CRA at a global clinical research organization and, after five years of serving in various monitoring positions, entered project management specializing in hematology and oncology drug development.

"Mr. Melvin is an exceptional addition to our team," said Krista Armstrong, Ph.D., Vice President, Clinical Trial Management. "As we continue to expand our presence within the oncology market, Mr. Melvin's substantial clinical and management expertise will be beneficial in continuing to establish Premier Research as an industry leader."

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging their commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and operates in more than 30 countries across Europe and North America. They employ a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at a well-established network of dedicated clinical sites.


'/>"/>
SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
2. Premier Research Appoints Global Head of Human Resources
3. Premier Research Appoints Melissa Jones as Vice President, International Business Development
4. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
7. Association of Clinical Research Organizations (ACRO) Elects New Officers for 2008
8. Biomoda Hires Senior Scientist to Expand Research & Development Effort
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
11. Researchers use magnetism to target cells to animal arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... and MENLO PARK, Calif. , ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on ... that it will present at the 18 th ... 8, 2016 at 10:00 a.m. EST in New ... DelMar,s president and CEO, will provide an update on the ...
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
Breaking Biology Technology:
(Date:1/8/2016)... LOS ANGELES and MANCHESTER, United Kingdom ... ("BBI"), a developer of innovative sensor-based diagnostic products, today ... was financed by new and existing investors.  Proceeds from the ... SEM Scanner , a hand-held device for detecting early-stage ... and Ireland after receiving CE Mark ...
(Date:1/7/2016)... 7, 2016 Various factors have contributed ... such as biologics and biosimilars. Some of these ... expenditure, growing demand for cost-effective alternatives, growing burden ... are similar versions of their corresponding patented biologic ... quality, safety, and efficacy. The global biosimilars market ...
(Date:1/6/2016)... 2016 Based on its recent analysis ... recognizes MorphoTrak, LLC, a U.S. subsidiary of Morpho ... Sullivan Company of the Year Award. The success ... Wave™ , has consolidated the company,s position as ... Morpho Wave is a highly accurate and ...
Breaking Biology News(10 mins):